| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2010.28.9793 |
| P8608 | Fatcat ID | release_5ji4npt6oba5vjfujownqa4njy |
| P932 | PMC publication ID | 2954133 |
| P698 | PubMed publication ID | 20697067 |
| P50 | author | Robert Tibshirani | Q3938444 |
| Freda K. Stevenson | Q39978824 | ||
| Richard T. Hoppe | Q91183516 | ||
| Ranjana H. Advani | Q102148850 | ||
| P2093 | author name string | Susan J Knox | |
| Lewis K Shin | |||
| Youn H Kim | |||
| Ronald Levy | |||
| Joshua D Brody | |||
| Irene Wapnir | |||
| Mia Levy | |||
| James A Torchia | |||
| Weiyun Z Ai | |||
| Debra K Czerwinski | |||
| P2860 | cites work | Calreticulin exposure dictates the immunogenicity of cancer cell death | Q28280438 |
| Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma | Q30419228 | ||
| Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma | Q33372646 | ||
| Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer | Q33470429 | ||
| Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma | Q35849633 | ||
| The clinical course of follicular lymphoma | Q36031839 | ||
| Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors | Q37039146 | ||
| Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma | Q37047969 | ||
| Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells | Q37073655 | ||
| LesionViewer: a tool for tracking cancer lesions over time | Q37128662 | ||
| Randomized clinical studies of anti-tumor vaccination: state of the art in 2008. | Q37354177 | ||
| Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma | Q37394755 | ||
| Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees | Q37420514 | ||
| The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells | Q38355683 | ||
| Topical CpG enhances the response of murine malignant melanoma to dacarbazine | Q39998237 | ||
| Successful combination of local CpG-ODN and radiotherapy in malignant glioma | Q40427349 | ||
| Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma | Q42435785 | ||
| Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors | Q43475849 | ||
| Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients | Q43893055 | ||
| Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly | Q44901072 | ||
| Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. | Q46106546 | ||
| Revised response criteria for malignant lymphoma | Q47582438 | ||
| Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. | Q51961830 | ||
| Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy. | Q51968607 | ||
| Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. | Q51989383 | ||
| High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. | Q53253117 | ||
| Detailed kinetics of immune responses to a new cell culture-derived smallpox vaccine in vaccinia-naïve adults. | Q53567274 | ||
| High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. | Q53983197 | ||
| Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells | Q73386737 | ||
| Immune responses to vaccinia and influenza elicited during primary versus recent or distant secondary smallpox vaccination of adults | Q79172692 | ||
| Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma | Q80294344 | ||
| Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma | Q80556384 | ||
| Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself | Q80736139 | ||
| Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist | Q80981083 | ||
| Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma | Q81463912 | ||
| B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides | Q81474815 | ||
| Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients | Q81644055 | ||
| Idiotype vaccination for lymphoma: moving towards optimisation | Q83246426 | ||
| Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses | Q83930163 | ||
| P433 | issue | 28 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | toll-like receptor | Q408004 |
| P304 | page(s) | 4324-4332 | |
| P577 | publication date | 2010-08-09 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study | |
| P478 | volume | 28 |
| Q41593116 | "In situ" vaccination for systemic effects in follicular lymphoma |
| Q89964140 | A Novel C Type CpG Oligodeoxynucleotide Exhibits Immunostimulatory Activity In Vitro and Enhances Antitumor Effect In Vivo |
| Q38206719 | A brief personal history of cancer immunotherapy at Stanford: if these walls could talk…. |
| Q37371686 | A phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma |
| Q38259725 | A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma. |
| Q38541959 | ANTI-TUMOR IMMUNE RESPONSES INDUCED BY RADIOTHERAPY: A REVIEW. |
| Q42097323 | Abscopal but desirable: The contribution of immune responses to the efficacy of radiotherapy |
| Q49553757 | Abscopal effect of radiation on bone metastases of breast cancer: A case report |
| Q58695217 | Activation of viral defense signaling in cancer |
| Q38030484 | Active immunotherapy: current state of the art in vaccine approaches for NHL |
| Q104504312 | Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity |
| Q58787920 | Addressing the Adult Soft Tissue Sarcoma Microenvironment with Intratumoral Immunotherapy |
| Q36403509 | Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice |
| Q38574574 | Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations |
| Q38666304 | An Update on the Use of Immunotherapy in the Treatment of Lymphoma |
| Q91198313 | An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases |
| Q39377049 | Anti-tumor Activity of Toll-Like Receptor 7 Agonists |
| Q41930681 | Antigen Cross-Presentation and T-Cell Cross-Priming In Cancer Immunology And Immunotherapy |
| Q43974504 | Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy |
| Q64117420 | B-cell lymphomas present immunoglobulin neoantigens |
| Q39203685 | Barriers to Radiation-Induced In Situ Tumor Vaccination. |
| Q41009948 | Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies. |
| Q36907246 | Can abscopal effects of local radiotherapy be predicted by modeling T cell trafficking? |
| Q34859794 | Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. |
| Q36387028 | Cancer immunotherapy: Strategies for personalization and combinatorial approaches |
| Q26995638 | Cancer vaccines and T cell therapy |
| Q30239893 | Canine cancer immunotherapy studies: linking mouse and human |
| Q90478493 | Class C CpG Oligodeoxynucleotide Immunomodulatory Response in Aged Squirrel Monkey (Saimiri Boliviensis Boliviensis) |
| Q36449873 | Clinical opportunities in combining immunotherapy with radiation therapy |
| Q64244484 | Cold Tumors: A Therapeutic Challenge for Immunotherapy |
| Q37053881 | Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank |
| Q42375130 | Colorectal cancer-infiltrating T lymphocytes display a distinct chemokine receptor expression profile |
| Q34582640 | Combinations of immunotherapy and radiation in cancer therapy. |
| Q61448764 | Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer? |
| Q26991721 | Combining radiation and immunotherapy: a new systemic therapy for solid tumors? |
| Q27021428 | Combining radiotherapy and cancer immunotherapy: a paradigm shift |
| Q39387013 | Conjugate Vaccine Immunotherapy for Substance Use Disorder |
| Q35025722 | CpG DNA as a vaccine adjuvant. |
| Q26783826 | CpG Oligonucleotides as Cancer Vaccine Adjuvants |
| Q35204579 | CpG and non-CpG oligodeoxynucleotides directly costimulate mouse and human CD4+ T cells through a TLR9- and MyD88-independent mechanism |
| Q38036658 | CpG plus radiotherapy: a review of preclinical works leading to clinical trial |
| Q36600960 | CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model |
| Q42317483 | CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1. |
| Q89694191 | Cross Talk between Radiation and Immunotherapy: The Twain Shall Meet |
| Q34288183 | Cryotherapy with concurrent CpG oligonucleotide treatment controls local tumor recurrence and modulates HER2/neu immunity. |
| Q36268306 | Current clinical trials testing combinations of immunotherapy and radiation. |
| Q28235733 | Current prospects for RNA interference-based therapies |
| Q37967108 | Cutaneous lymphomas: molecular pathways leading to new drugs |
| Q36544893 | DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies |
| Q39330984 | Delivering safer immunotherapies for cancer |
| Q89347786 | Dendritic cell-based immunotherapy |
| Q36891034 | Depleting tumor-specific Tregs at a single site eradicates disseminated tumors |
| Q45060547 | Development of a Clinically Viable Heroin Vaccine. |
| Q90118200 | Development of an In Situ Cancer Vaccine via Combinational Radiation and Bacterial-Membrane-Coated Nanoparticles |
| Q35634752 | Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity |
| Q36194871 | Effect of CpG ODN on monocytic myeloid derived suppressor cells |
| Q34364876 | Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation |
| Q52596335 | Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. |
| Q38809772 | Emerging Opportunities and Challenges in Cancer Immunotherapy. |
| Q38763851 | Emerging immunotherapy for the treatment of esophageal cancer |
| Q37154783 | Encoded novel forms of HSP70 or a cytolytic protein increase DNA vaccine potency |
| Q39250390 | Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma |
| Q27025290 | Epithelial toll-like receptor 9 signaling in colorectal inflammation and cancer: clinico-pathogenic aspects |
| Q38553010 | Evolving synergistic combinations of targeted immunotherapies to combat cancer. |
| Q47940254 | Exploiting lymphatic vessels for immunomodulation: Rationale, opportunities, and challenges. |
| Q92648581 | Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFRL858R/T790M mutation |
| Q45952214 | From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. |
| Q92314002 | Functional Polymorphisms and Gene Expression of TLR9 Gene as Protective Factors for Nasopharyngeal Carcinoma Severity and Progression |
| Q35880618 | Haematological malignancies: at the forefront of immunotherapeutic innovation |
| Q26747695 | Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer? |
| Q37671216 | Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application |
| Q36628291 | High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. |
| Q61812341 | Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy |
| Q88213457 | Imaging activated T cells predicts response to cancer vaccines |
| Q26765115 | Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials |
| Q60548670 | Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect |
| Q37832694 | Immunomodulating antibodies and drugs for the treatment of hematological malignancies |
| Q60959909 | Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend |
| Q38821875 | Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop |
| Q64071120 | Immunotherapeutic effects of intratumoral nanoplexed poly I:C |
| Q52592731 | Immunotherapy Plus Cryotherapy: Potential Augmented Abscopal Effect for Advanced Cancers. |
| Q41831989 | Immunotherapy for B-cell lymphoma: current status and prospective advances |
| Q26852388 | Immunotherapy for prostate cancer: recent developments and future challenges |
| Q89626900 | Immunotherapy of lymphomas |
| Q94673411 | In Situ Therapeutic Cancer Vaccination with an Oncolytic Virus Expressing Membrane-Tethered IL-2 |
| Q35669197 | In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study |
| Q38727470 | In situ vaccination for the treatment of cancer. |
| Q38657642 | In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf. |
| Q36210670 | In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer |
| Q26991976 | In-situ tumor vaccination: Bringing the fight to the tumor |
| Q35119800 | Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy |
| Q37714150 | Injection route and TLR9 agonist addition significantly impact heroin vaccine efficacy |
| Q38991015 | Innate immune mediators in cancer: between defense and resistance |
| Q39041026 | Innate immune signaling and regulation in cancer immunotherapy |
| Q39325230 | Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer |
| Q39043844 | Intratumoral Delivery of Immunotherapy-Act Locally, Think Globally |
| Q90257528 | Intratumoral Immunotherapy-Update 2019 |
| Q37691837 | Intratumoral immunization: a new paradigm for cancer therapy |
| Q90066938 | Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies |
| Q47281370 | Intratumoral immunotherapy: using the tumor as the remedy |
| Q35740077 | Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells |
| Q37469720 | Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells |
| Q36090011 | Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas |
| Q52353493 | Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses. |
| Q41653193 | Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. |
| Q38031760 | Local targets for immune therapy to cancer: tumor draining lymph nodes and tumor microenvironment |
| Q36675055 | Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. |
| Q38181691 | Lung cancer: potential targets for immunotherapy |
| Q26782902 | Lymphoma Immunotherapy: Current Status |
| Q28080705 | Lymphoma: immune evasion strategies |
| Q49192661 | MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice |
| Q28080773 | Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer |
| Q35189915 | Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation |
| Q51712946 | Myeloid cell leukaemia 1 has a vital role in retinoic acid-mediated protection of Toll-like receptor 9-stimulated B cells from spontaneous and DNA damage-induced apoptosis. |
| Q94474333 | Nanomedicines based on nanoscale metal-organic frameworks for cancer immunotherapy |
| Q45921466 | Natural toll-like receptor agonists in prophylactic vaccines for dendritic cell activation. |
| Q33859105 | Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival |
| Q58804962 | New developments in immunotherapy for lymphoma |
| Q37275610 | Non-clinical safety evaluation of repeated intramuscular administration of the AS15 immunostimulant combined with various antigens in rabbits and cynomolgus monkeys |
| Q64075507 | Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy |
| Q36161365 | Novel therapeutic agents for cutaneous T-Cell lymphoma |
| Q36586115 | Oligodeoxynucleotides expressing polyguanosine motifs promote antitumor activity through the upregulation of IL-2. |
| Q90733371 | PD-1 blockade enhances radio-immunotherapy efficacy in murine tumor models |
| Q38358045 | Paradigm shift in oncology: targeting the immune system rather than cancer cells |
| Q38690773 | Pattern recognition receptors: immune targets to enhance cancer immunotherapy |
| Q37384289 | Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project |
| Q61797413 | Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer |
| Q35699010 | Plasmacytoid dendritic cells lead the charge against tumors |
| Q36347177 | Radiation as an immunological adjuvant: current evidence on dose and fractionation. |
| Q47703452 | Radiation effects on antitumor immune responses: current perspectives and challenges |
| Q26865395 | Radiation for Awakening the Dormant Immune System, a Promising Challenge to be Explored |
| Q27005913 | Radiation meets immunotherapy - a perfect match in the era of combination therapy? |
| Q36083353 | Radiation takes its Toll |
| Q42270394 | Radiation therapy to convert the tumor into an in situ vaccine |
| Q47592083 | Radiation-enhanced delivery of systemically administered amphiphilic-CpG oligodeoxynucleotide |
| Q60954603 | Radiotherapy as a New Player in Immuno-Oncology |
| Q26738443 | Radiotherapy combination opportunities leveraging immunity for the next oncology practice |
| Q38845317 | Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study |
| Q64927862 | Radiotherapy in Combination With Cytokine Treatment. |
| Q92306380 | Rational combinations of immunotherapy with radiotherapy in ovarian cancer |
| Q44607083 | Re-inventing intratumoral immunotherapy for melanoma |
| Q30456436 | Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop |
| Q34657329 | Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma |
| Q38168903 | Recent progress concerning CpG DNA and its use as a vaccine adjuvant |
| Q38033592 | Relapsed or refractory pediatric acute lymphoblastic leukemia: current and emerging treatments |
| Q91148338 | Renewed interest for low-dose radiation therapy in follicular lymphomas: From biology to clinical applications |
| Q38149916 | Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions |
| Q36186619 | Role of T lymphocytes in tumor response to radiotherapy |
| Q47122380 | STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy |
| Q39389951 | STING-mediated DNA sensing in cancer immunotherapy |
| Q33413438 | Safety of Toll-like receptor 9 agonists: a systematic review and meta-analysis |
| Q38279548 | Self-adjuvanting lipoimmunogens for therapeutic HPV vaccine development: potential clinical impact |
| Q40945758 | Special Conference on Tumor Immunology and Immunotherapy: A New Chapter |
| Q57180378 | Starting the Fight in the Tumor: Expert Recommendations for the Development of Human Intratumoral Immunotherapy (HIT-IT) |
| Q46189367 | Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control |
| Q38841677 | Strategies for designing synthetic immune agonists |
| Q46962194 | Subverting misconceptions about radiation therapy |
| Q37505384 | Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas. |
| Q36476394 | Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer |
| Q47739711 | Synthetic immune niches for cancer immunotherapy |
| Q63101722 | Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination |
| Q36827406 | Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models |
| Q41917657 | T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy |
| Q36850457 | TLR agonists: our best frenemy in cancer immunotherapy |
| Q37567832 | TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiotherapy |
| Q34320769 | TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo |
| Q64084601 | Targeted APC Activation in Cancer Immunotherapy to Enhance the Abscopal Effect |
| Q37991536 | Targeting pattern recognition receptors in cancer immunotherapy. |
| Q35176307 | Targeting the tumor microenvironment to enhance antitumor immune responses |
| Q64091333 | The Role of Radiation Oncology in Immuno-Oncology |
| Q37640319 | The Roles of Radiotherapy and Immunotherapy for the Treatment of Lymphoma |
| Q64911658 | The Significant Reduction or Complete Eradication of Subcutaneous and Metastatic Lesions in a Pheochromocytoma Mouse Model after Immunotherapy Using Mannan-BAM, TLR Ligands, and Anti-CD40. |
| Q89892410 | The abscopal effect 67 years later: from a side story to center stage |
| Q38054113 | The confluence of radiotherapy and immunotherapy |
| Q47097756 | The current status of immunobased therapies for metastatic renal-cell carcinoma |
| Q34373036 | The dark side of Toll-like receptor signaling: TLR9 activation limits the efficacy cancer radiotherapy |
| Q38209978 | The early history of Stanford Immunology |
| Q37042237 | The host STING pathway at the interface of cancer and immunity |
| Q37518395 | The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications |
| Q37181696 | The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade |
| Q35018021 | The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. |
| Q38294283 | The proprotein convertase PC1/3 regulates TLR9 trafficking and the associated signaling pathways. |
| Q38021845 | The role of antigen-specific and non-specific immunotherapy in the treatment of cancer |
| Q37981038 | The secret ally: immunostimulation by anticancer drugs |
| Q42372842 | Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going? |
| Q92629429 | Therapeutic vaccination immunomodulation: forming the basis of all cancer immunotherapy |
| Q50689529 | Thermosensitive Gel-Based Formulation for Intratumoral Delivery of Toll-Like Receptor 7/8 Dual Agonist, MEDI9197. |
| Q35328686 | Three steps to breaking immune tolerance to lymphoma: a microparticle approach. |
| Q37831323 | Toll-like receptor 9 agonists as cancer therapeutics |
| Q36583710 | Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning |
| Q38103581 | Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies |
| Q37295411 | Toll-like receptors in prostate infection and cancer between bench and bedside |
| Q38656599 | Towards precision radiotherapy for use with immune checkpoint blockers. |
| Q42847992 | Trial Watch: Anticancer radioimmunotherapy |
| Q36194849 | Trial Watch: Experimental Toll-like receptor agonists for cancer therapy |
| Q57394699 | Trial Watch: Toll-like receptor agonists in cancer immunotherapy |
| Q49958115 | Using immunotherapy to boost the abscopal effect |
| Q37929157 | Vaccination strategies in lymphomas and leukaemias: recent progress |
| Q39043404 | Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update |
| Q90468303 | Warming up the tumor microenvironment in order to enhance immunogenicity |
| Q43231874 | Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011. |
Search more.